Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment

World Journal of Hepatology

Volumn 8, Issue 2, 2016, Pages 83-91

  Pastore, Francesca ^a   Martocchia, Antonio ^a   Stefanelli, Manuela ^a   Prunas, Pietro ^a   Giordano, Stefania ^a   Toussan, Lavinia ^a   Devito, Antonio ^a   Falaschi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiviral agents; Hepatitis C virus; Interferon; Self tolerance; Thyroid autoimmunity

Indexed keywords

EID: 84954457958     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v8.i2.83     Document Type: Article

References (109)

1. Zignego AL, Gragnani L, Piluso A, Sebastiani M, Giuggioli D, Fallahi P, Antonelli A, Ferri C. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol 2015; 11: 15-31 [PMID: 25534977 DOI: 10.1586/1744666X.2015.997214]
2. Jadali Z, Alavian SM. Autoimmune diseases co-existing with hepatitis C virus infection. Iran J Allergy Asthma Immunol 2010; 9: 191-206 [PMID: 21131699]
3. Martocchia A, Stefanelli M, Cola S, Falaschi P. Sex steroids in autoimmune diseases. Curr Top Med Chem 2011; 11: 1668-1683 [PMID: 21463254 DOI: 10.2174/156802611796117595]
4. Poletaev AB, Stepanyuk VL, Gershwin ME. Integrating immunity: the immunculus and self-reactivity. J Autoimmun 2008; 30: 68-73 [PMID: 18191542 DOI: 10.1016/j.jaut.2007.11.012]
5. Adams DD, Purves HD. Abnormal responses in the assay of thyrotrophin. Proc Univer Otago Med School 1956; 34: 11-12
6. Roitt IM, Doniach D, Campbell PN, Hudson RV. Auto-antibodies in Hashimoto's disease (lymphadenoid goitre). Lancet 1956; 271: 820-821 [PMID: 13368530 DOI: 10.1016/S0140-6736(56)92249-8]
7. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2: 933-944 [PMID: 12461566 DOI: 10.1038/nri954]
8. Corthay A. How do regulatory T cells work? Scand J Immunol 2009;70: 326-336 [PMID: 19751267 DOI: 10.1111/j.1365-3083.2009.02308.x]
9. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793 [PMID: 8893001 DOI: 10.1038/383787a0]
10. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051-1057 [PMID: 18563156 DOI: 10.1038/nature07036]
11. Watanabe M, Nakamura Y, Matsuzuka F, Takamura Y, Miyauchi A, Iwatani Y. Decrease of intrathyroidal CD161+Valpha24+Vbeta11+ NKT cells in Graves' disease. Endocr J 2008; 55: 199-203 [PMID: 18250538 DOI: 10.1507/endocrj.K07E-006]
12. Nada AM, Hammouda M. Immunoregulatory T cells, LFA-3 and HLA-DR in autoimmune thyroid diseases. Indian J Endocrinol Metab 2014; 18: 574-581 [PMID: 25143920 DOI: 10.4103/2230-8210.137524]
13. McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev 2014;35: 59-105 [PMID: 24091783 DOI: 10.1210/er.2013-1055]
14. Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN. Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid 2013; 23: 871-878 [PMID: 23379353 DOI: 10.1089/thy.2012.0514]
15. Rodríguez-Muñoz A, Vitales-Noyola M, Ramos-Levi A, Serrano-Somavilla A, González-Amaro R, Marazuela M. Levels of regulatory T cells CD69(+)NKG2D (+)IL-10 (+) are increased in patients with autoimmune thyroid disorders. Endocrine 2015; Epub ahead of print [PMID: 26100786]
16. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145 [PMID: 17290272 DOI: 10.1038/nm1551]
17. Li D, Cai W, Gu R, Zhang Y, Zhang H, Tang K, Xu P, Katirai F, Shi W, Wang L, Huang T, Huang B. Th17 cell plays a role in the pathogenesis of Hashimoto's thyroiditis in patients. Clin Immunol 2013; 149: 411-420 [PMID: 24211715 DOI: 10.1016/j.clim.2013.10.001]
18. Vural P, Degirmencioglu S, Erden S, Gelincik A. The relationship between transforming growth factor-beta1, vascular endothelial growth factor, nitric oxide and Hashimoto's thyroiditis. Int Immunopharmacol 2009; 9: 212-215 [PMID: 19028605 DOI: 10.1016/j.intimp.2008.11.003]
19. de la Vega JR, Vilaplana JC, Biro A, Hammond L, Bottazzo GF, Mirakian R. IL-10 expression in thyroid glands: protective or harmful role against thyroid autoimmunity? Clin Exp Immunol 1998;113: 126-135 [PMID: 9697995]
20. Shimaoka Y, Hidaka Y, Okumura M, Takeoka K, Tada H, Amino N. Serum concentration of soluble Fas in patients with autoimmune thyroid diseases. Thyroid 1998; 8: 43-47 [PMID: 9492152]
21. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003; 24: 694-717 [PMID: 14570752 DOI: 10.1210/er.2002-0030]
22. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 2003; 148: 1-9 [PMID: 12534350 DOI: 10.1530/eje.0.1480001]
23. Ban Y, Tozaki T, Tobe T, Ban Y, Jacobson EM, Concepcion ES, Tomer Y. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts. J Autoimmun 2007; 28: 201-207 [PMID: 17418529 DOI: 10.1016/j.jaut.2007.02.016]
24. Bech K, Lumholtz B, Nerup J, Thomsen M, Platz P, Ryder LP, Svejgaard A, Siersbaek-Nielsen K, Hansen JM, Larsen JH. HLA antigens in Graves' disease. Acta Endocrinol (Copenh) 1977; 86: 510-516 [PMID: 72471 DOI: 10.1530/acta.0.0860510]
25. Brix TH, Kyvik KO, Hegedus L. What is evidence of genetic factor in the aetiology of Graves' disease? A brief review. Thyroid 1998;8: 627-634 [DOI: 10.1089/thy.1998.8.627]
26. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995; 108: 157-164 [PMID: 7806037 DOI: 10.1016/0016-5085(95)90020-9]
27. Hall R, Owen SG, Smart GA. Evidence for genetic predisposition to formation of thyroid autoantibodies. Lancet 1960; 2: 187-188 [PMID: 14399065]
28. Hunt PJ, Marshall SE, Weetman AP, Bunce M, Bell JI, Wass JA, Welsh KI. Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2001; 55: 491-499 [PMID: 11678832 DOI: 10.1046/j.1365-2265.2001.01356.x]
29. Jacobson EM, Huber AK, Akeno N, Sivak M, Li CW, Concepcion E, Ho K, Tomer Y. A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun 2007; 8: 205-214 [PMID: 17344890 DOI: 10.1038/sj.gene.6364375]
30. Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 1999; 30: 794-800 [PMID: 10365804 DOI: 10.1016/S0168-8278(99)80131-7]
31. Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davies TF. A new Graves disease-susceptibility locus maps to chromosome 20q11.2. International Consortium for the Genetics of Autoimmune Thyroid Disease. Am J Hum Genet 1998; 63: 1749-1756 [PMID: 9837828 DOI: 10.1086/302146]
32. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995; 80: 41-45 [PMID: 7829637 DOI: 10.1210/jc.80.1.41]
33. Höhler T, Gerken G, Notghi A, Knolle P, Lubjuhn R, Taheri H, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 1997; 27: 259-264 [PMID: 9288598]
34. Roederer M, Quaye L, Mangino M, Beddall MH, Mahnke Y, Chattopadhyay P, Tosi I, Napolitano L, Terranova Barberio M, Menni C, Villanova F, Di Meglio P, Spector TD, Nestle FO. The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis. Cell 2015; 161: 387-403 [PMID: 25772697 DOI: 10.1016/j.cell.2015.02.046]
35. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001; 2: 777-780 [PMID: 11526384 DOI: 10.1038/ni0901-777]
36. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology 2012; 55: 759-768 [PMID: 21858849 DOI: 10.1002/hep.24618]
37. White DL, Liu Y, Garcia J, El-Serag HB, Jiao L, Tsavachidis S, Franco LM, Lee JS, Tavakoli-Tabasi S, Moore D, Goldman R, Kuzniarek J, Ramsey DJ, Kanwal F, Marcelli M. Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males. Int J Mol Epidemiol Genet 2014; 5: 164-176 [PMID: 25379136]
38. Sternberg EM. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol 2001; 169: 429-435 [PMID: 11375112 DOI: 10.1677/joe.0.1690429]
39. Tran HA, Reeves GE, Lyons TJ, Attia JR. Histopathologic findings of autoimmunity in thyroid, pituitary, and adrenal diseases in chronic hepatitis C postmortem cases. Endocr Pract 2010; 16: 566-569 [PMID: 20150020 DOI: 10.4158/EP09359.OR]
40. Menconi F, Huber A, Osman R, Concepcion E, Jacobson EM, Stefan M, David CS, Tomer Y. Tg.2098 is a major human thyroglobulin T-cell epitope. J Autoimmun 2010; 35: 45-51 [PMID: 20303712 DOI: 10.1016/j.jaut.2010.01.004]
41. Yin X, Latif R, Bahn R, Tomer Y, Davies TF. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy. Thyroid 2008; 18: 1201-1206 [PMID: 18925838 DOI: 10.1089/thy.2008.0098]
42. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol 2014; 9: 147-156 [PMID: 24460189 DOI: 10.1146/annurev-pathol-012513-104713]
43. Winsa B, Adami HO, Bergström R, Gamstedt A, Dahlberg PA, Adamson U, Jansson R, Karlsson A. Stressful life events and Graves' disease. Lancet 1991; 338: 1475-1479 [PMID: 1683917 DOI: 10.1016/0140-6736(91)92298-G]
44. Chiovato L, Pinchera A. Stressful life events and Graves' disease. Eur J Endocrinol 1996; 134: 680-682 [PMID: 8766933 DOI: 10.1530/eje.0.1340680]
45. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-1695 [PMID: 10568572 DOI: 10.1016/S0140-6736(99)02429-0]
46. Ruwhof C, Drexhage HA. Iodine and thyroid autoimmune disease in animal models. Thyroid 2001; 11: 427-436 [PMID: 11396701 DOI: 10.1089/105072501300176381]
47. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15: 788-830 [PMID: 7705281 DOI: 10.1210/er.15.6.788]
48. Burman P, Tötterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocytederived interferon. J Clin Endocrinol Metab 1986; 63: 1086-1090 [PMID: 2944910 DOI: 10.1210/jcem-63-5-1086]
49. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY, Chang WY. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000; 142: 431-437 [PMID: 10802518 DOI: 10.1530/eje.0.1420431]
50. Lunel F. Hepatitis C virus and autoimmunity: fortuitous association or reality? Gastroenterology 1994; 107: 1550-1555 [PMID: 7523229 DOI: 10.1016/0016-5085(94)90564-9]
51. Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7: 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616]
52. Smith B, Falck-Ytter Y. Guidelines for the screening, care and treatment of persons with hepatitis C infection. WHO Library Cataloguing-in-Publication Data, 2014
53. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385: 1124-1135 [PMID: 25687730 DOI: 10.1016/S0140-6736(14)62401-6]
54. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007; 39 Suppl 1: S13-S21 [PMID: 17936215 DOI: 10.1016/S1590-8658(07)80005-3]
55. Calvaruso V, Craxì A. Immunological alterations in hepatitis C virus infection. World J Gastroenterol 2013; 19: 8916-8923 [PMID: 24379616 DOI: 10.3748/wjg.v19.i47.8916]
56. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102: 18544-18549 [PMID: 16339892 DOI: 10.1073/pnas.0509402102]
57. Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, Abrignani S, Grandi G. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 2000; 74: 4824-4830 [PMID: 10775621 DOI: 10.1128/JVI.74.10.4824-4830.2000]
58. Apolinario A, Majano PL, Lorente R, Núñez O, Clemente G, García-Monzón C. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J Viral Hepat 2005; 12: 27-37 [PMID: 15655045 DOI: 10.1111/j.1365-2893.2005.00540.x]
59. Akeno N, Blackard JT, Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun 2008; 31: 339-344 [PMID: 18799285 DOI: 10.1016/j.jaut.2008.08.001]
60. Danilovic DL, Mendes-Correa MC, Chammas MC, Zambrini H, Barros RK, Marui S. Thyroid disturbance related to chronic hepatitis C infection: role of CXCL10. Endocr J 2013; 60: 583-590 [PMID: 23291435]
61. Broussolle C, Steineur MP, Bailly F, Zoulim F, Trépo C. [Hepatitis C virus infection and thyroid diseases]. Rev Med Interne 1999;20: 766-773 [PMID: 10522298 DOI: 10.1016/S0248-8663(00)88683-X]
62. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001; 86: 1925-1929 [PMID: 11344186 DOI: 10.1210/jcem.86.5.7459]
63. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 1998; 158: 1445-1448 [PMID: 9665354 DOI: 10.1001/archinte.158.13.1445]
64. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999; 50: 503-509 [PMID: 10468911 DOI: 10.1046/j.1365-2265.1999.00686.x]
65. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206-210 [PMID: 9214471 DOI: 10.1002/hep.510260127]
66. Ganne-Carrie N, Medini A, Coderc E, Seror O, Christidis C, Grimbert S, Trinchet JC, Beaugrand M. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun 2000; 14: 189-193 [PMID: 10677250 DOI: 10.1006/jaut.1999.0360]
67. Marazuela M, García-Buey L, González-Fernández B, García-Monzón C, Arranz A, Borque MJ, Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44: 635-642 [PMID: 8759175 DOI: 10.1046/j.1365-2265.1996.751768.x]
68. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22: 364-369 [PMID: 7608489 DOI: 10.1016/0168-8278(95)80291-6]
69. Oppenheim Y, Ban Y, Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmun Rev 2004; 3: 388-393 [PMID: 15288006 DOI: 10.1016/j.autrev.2004.03.003]
70. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003; 13: 547-551 [PMID: 12930598 DOI: 10.1089/105072503322238809]
71. Rocco A, Gargano S, Provenzano A, Nardone M, De Sanctis GM, Altavilla N, Chircu LV, Grimaldi F. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuro Endocrinol Lett 2001; 22: 39-44 [PMID: 11335878]
72. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 2007;36: 1051-1066; x-xi [PMID: 17983936 DOI: 10.1016/j.ecl.2007.07.001]
73. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, Weissel M. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90: 363-367 [PMID: 1458673 DOI: 10.1111/j.1365-2249.1992.tb05852.x]
74. Yamazaki K, Kanaji Y, Shizume K, Yamakawa Y, Demura H, Kanaji Y, Obara T, Sato K. Reversible inhibition by interferons alpha and beta of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab 1993; 77: 1439-1441 [PMID: 8077347 DOI: 10.1210/jc.77.5.1439]
75. McCann SM, Lyson K, Karanth S, Gimeno M, Belova N, Kamat A, Rettori V. Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection. Ann N Y Acad Sci 1995; 771: 386-395 [PMID: 8597416 DOI: 10.1111/j.1749-6632.1995. tb44697.x]
76. Ryu SY, Jeong KS, Yoon WK, Park SJ, Kang BN, Kim SH, Park BK, Cho SW. Somatostatin and substance P induced in vivo by lipopolysaccharide and in peritoneal macrophages stimulated with lipopolysaccharide or interferon-gamma have differential effects on murine cytokine production. Neuroimmunomodulation 2000; 8: 25-30 [PMID: 10859485 DOI: 10.1159/000026449]
77. Falaschi P, D'Urso R, Proietti A, Martocchia A, Pastore R, Angelucci L. Effect of r-interferon alpha administration on hypothalamus-pituitary-thyroid axis in chronic hepatitis. Life Sci 1997; 60: 43-50 [PMID: 8995531 DOI: 10.1016/S0024-3205(96)00587-5]
78. Falaschi P, Martocchia A, D'Urso R, Proietti A. Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C. J Endocrinol Invest 1997; 20: 24-28 [PMID: 9075068 DOI: 10.1007/BF03347968]
79. Hall R. Subacute (De Quervain's) thyroiditis. In: Hall R, Besser GM. Fundamentals of clinical endocrinology. Churchill Livingstone: Edimburgh, 1989: 101
80. Nyulassy S, Hnilica P, Buc M, Guman M, Hirschová V, Stefanovic J. Subacute (de Quervain's) thyroiditis: association with HLA-Bw35 antigen and abnormalities of the complement system, immunoglobulins and other serum proteins. J Clin Endocrinol Metab 1977; 45: 270-274 [PMID: 885992 DOI: 10.1210/jcem-45-2-270]
81. Romagnani S. Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? Immunol Today 1992; 13: 379-381 [PMID: 1418371 DOI: 10.1016/0167-5699(92)90083-J]
82. Martocchia A, Labbadia G, Paoletti V, Gargano S, Grossi A, Trabace S, Musca A, Falaschi P. Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro Endocrinol Lett 2001; 22: 49-52 [PMID: 11335880]
83. Grimaldi F, Martocchia A, Lulli P, Frugoni P, Fiore RF, Rossi C, Ferrari F, Labbadia G, Falaschi P. Frequenza degli alleli HLA nei pazienti affetti da epatite cronica HCV-correlata e predisposizione alla comparsa della patologia tiroidea immuno-mediata dopo trattamento antivirale. Int Emerg Med 2009; 4: S84
84. Ohsako N, Tamai H, Sudo T, Mukuta T, Tanaka H, Kuma K, Kimura A, Sasazuki T. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing. J Clin Endocrinol Metab 1995; 80: 3653-3656 [PMID: 8530615]
85. Chen QY, Huang W, She JX, Baxter F, Volpe R, Maclaren NK. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab 1999; 84: 3182-3186 [PMID: 10487684]
86. Dalton TA, Bennett JC. Autoimmune disease and the major histocompatibility complex: therapeutic implications. Am J Med 1992;92: 183-188 [PMID: 1543203 DOI: 10.1016/0002-9343(92)90110-W]
87. Heward JM, Allahabadia A, Daykin J, Carr-Smith J, Daly A, Armitage M, Dodson PM, Sheppard MC, Barnett AH, Franklyn JA, Gough SC. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. J Clin Endocrinol Metab 1998; 83: 3394-3397 [PMID: 9768636 DOI: 10.1210/jc.83.10.3394]
88. Kinney JS, Hurwitz ES, Fishbein DB, Woolf PD, Pinsky PF, Lawrence DN, Anderson LJ, Holmes GP, Wilson CK, Loschen DJ. Community outbreak of thyrotoxicosis: epidemiology, immunogenetic characteristics, and long-term outcome. Am J Med 1988;84: 10-18 [PMID: 3257352 DOI: 10.1016/0002-9343(88)90002-2]
89. Zamani M, Spaepen M, Bex M, Bouillon R, Cassiman JJ. Primary role of the HLA class II DRB1*0301 allele in Graves disease. Am J Med Genet 2000; 95: 432-437 [PMID: 11146462 DOI: 10.1002/1096-8628(20001218)95]
90. Farid NR, Sampson L, Moens H, Barnard JM. The association of goitrous autoimmune thyroiditis with HLA-DR5. Tissue Antigens 1981; 17: 265-268 [PMID: 6947505 DOI: 10.1111/j.1399-0039.1981.tb00700.x]
91. Bogner U, Badenhoop K, Peters H, Schmieg D, Mayr WR, Usadel KH, Schleusener H. HLA-DR/DQ gene variation in nongoitrous autoimmune thyroiditis at the serological and molecular level. Autoimmunity 1992; 14: 155-158 [PMID: 1363895 DOI: 10.1089/thy.2012.0507]
92. Pocecco M, Barbi E, De Campo C. [Autoimmune thyroid pathology. Study and follow-up of pediatric case reports]. Pediatr Med Chir 1986; 8: 691-694 [PMID: 3496586]
93. Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, Tomer Y. Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci USA 2008; 105: 14034-14039 [PMID: 18779568 DOI: 10.1073/pnas.0806584105]
94. Sarobe P, Huarte E, Lasarte JJ, López-Díaz de Cerio A, García N, Borrás-Cuesta F, Prieto J. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. J Hepatol 2001; 34: 321-329 [PMID: 11281563 DOI: 10.1016/S0168-8278(00)00018-0]
95. Vertuani S, Bazzaro M, Gualandi G, Micheletti F, Marastoni M, Fortini C, Canella A, Marino M, Tomatis R, Traniello S, Gavioli R. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 2002; 32: 144-154 [PMID: 11754355 DOI: 10.1002/1521-4141(200201)32:1]
96. Brazillet MP, Batteux F, Abehsira-Amar O, Nicoletti F, Charreire J. Induction of experimental autoimmune thyroiditis by heat-denatured porcine thyroglobulin: a Tc1-mediated disease. Eur J Immunol 1999; 29: 1342-1352 [PMID: 10229102 DOI: 10.1002/(S ICI)1521-4141(199904)29]
97. Iwatani Y, Amino N, Hidaka Y, Kaneda T, Ichihara K, Tamaki H, Matsuzuka F, Fukata S, Kuma K, Miyai K. Decreases in alpha beta T cell receptor negative T cells and CD8 cells, and an increase in CD4+ CD8+ cells in active Hashimoto's disease and subacute thyroiditis. Clin Exp Immunol 1992; 87: 444-449 [PMID: 1347493 DOI: 10.1111/j.1365-2249.1992.tb03017.x]
98. Blackard JT, Kong L, Huber AK, Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid 2013; 7: 863-870 [PMID: 2325973]
99. Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, Lloyd AR, Beard MR. The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. J Biol Chem 2015; 290: 25946-25959 [PMID: 26354436]
100. Martocchia A, Falaschi P. Amino acid sequence homologies between HCV polyprotein and thyroid antigens. Intern Emerg Med 2007;2: 65-67 [PMID: 17551693]
101. Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Conception E, Fadlalla M, Ho K, Tomer Y. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286: 31168-31179 [PMID: 21757724 DOI: 10.1074/jbc.M111.247510]
102. Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB, Owen R, Zhang W, Tomer Y. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci USA 2014; 111: 12562-12567 [PMID: 25122677]
103. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244 [PMID: 12407599 DOI: 10.1002/hep.1840360730]
104. Hunyady B, Kovács B, Battyáni Z. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Orv Hetil 2011; 152: 1997-2009 [PMID: 23259732 DOI: 10.1556/OH.2011.29266]
105. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
106. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644 [PMID: 12939590 DOI: 10.1053/jhep.2003.50350]
107. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603 [PMID: 24720703 DOI: 10.1056/NEJMoa1315722]
108. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]
109. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992 [PMID: 24795200 DOI: 10.1056/NEJMoa1402338]